Results 91 to 100 of about 46,918 (102)

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial

Blood, 2015
Petra Langerbeins, Stephan Stilgenbauer, Anna Maria Fink   +2 more
exaly  

Comparison of the in vitro effects of the anti‐CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells

British Journal of Haematology, 2011
Christian Klein, Gunter Krause
exaly  

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Blood, 2011
Christian Klein, Karl-Peter Hopfner, Manfred Schwaiger   +2 more
exaly  

CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial

Blood, 2016
Stephan Stilgenbauer, , Jasmin Bahlo
exaly  

Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia.

Blood, 2009
Catherine Thieblemont, Guillaume Cartron, Cartron Guillaume   +2 more
exaly  

Compared Antitumor Activity of GA101 and Rituximab against the Human RL Follicular Lymphoma Xenografts in SCID Beige Mice.

Blood, 2008
Christian Klein, , Charles Dumontet
exaly  

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.

Blood, 2007
Christian Klein, Umana Pablo, Sondermann Peter   +2 more
exaly  

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

Blood, 2012
Gilles A Salles, Catherine Thieblemont, Guillaume Cartron   +2 more
exaly  

Encouraging Activity of Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma: Results From a Phase II Study (BO20999),

Blood, 2011
Cartron Guillaume, Milpied Noel, Bouabdallah Reda   +2 more
exaly  

Enhanced Activity of GA101, a Novel Type II, Glycoengineered CD20 Antibody, In Combination with Bendamustine or Fludarabine, and with the Bcl-2 Family Inhibitors ABT-737 or ABT-263

Blood, 2010
Christian Klein, Umana Pablo, Frank Herting   +2 more
exaly